← Back to Search

Adenosine 2A Receptor Agonist

Regadenoson infusion for Lung Transplant

Phase 1
Waitlist Available
Research Sponsored by Christine Lau, MD
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 72 hours
Awards & highlights

Study Summary

This trial will assess the maximum safe dose and duration of regadenoson that can be given to people undergoing a lung transplant.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~72 hours
This trial's timeline: 3 weeks for screening, Varies for treatment, and 72 hours for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Patient tolerability of assigned dose and duration
Secondary outcome measures
Activation of iNKT cells
Clinical Pulmonary Graft Dysfunction (PGD) score
Inflammatory Cytokines in blood and bronchioalveolar lavage

Trial Design

1Treatment groups
Experimental Treatment
Group I: Regadenoson infusionExperimental Treatment1 Intervention
Dose escalation of Regadenoson infusion

Find a Location

Who is running the clinical trial?

National Heart, Lung, and Blood Institute (NHLBI)NIH
3,837 Previous Clinical Trials
47,851,573 Total Patients Enrolled
3 Trials studying Lung Transplant
167 Patients Enrolled for Lung Transplant
Christine Lau, MDLead Sponsor

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
The Journal of Heart and Lung TransplantationJournal
Adenosine A2A Receptor Agonist (regadenoson) in Human Lung Transplantation
Lau, Christine L., Jared P. Beller, Joshua A. Boys, Yunge Zhao, Jennifer Phillips, Michael Cosner, Mark R. Conaway, et al.. 2020. “Adenosine A2A Receptor Agonist (regadenoson) in Human Lung Transplantation”. The Journal of Heart and Lung Transplantation. Elsevier BV. doi:10.1016/j.healun.2020.02.003.
clinicaltrials.govStudy
Study to Evaluate Adenosine 2A Receptor Agonist (Regadenoson) in Patients Undergoing Lung Transplantation
Christine Lau, MD 2017. "Study to Evaluate Adenosine 2A Receptor Agonist (Regadenoson) in Patients Undergoing Lung Transplantation". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03072589.
~3 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top